Dexfenfluramine

Summary

Dexfenfluramine (CHEMBL248702) is an approved small-molecule appetite depressant (ATC A08AA04); indicated across 1 condition including obesity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A08AA04
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 231.26 Da · C12H16F3N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL248702
Name	Dexfenfluramine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	66265
ChEBI	CHEBI:439329
ATC	A08AA04
Molecular formula	C12H16F3N
Molecular weight	231.26
InChIKey	DBGIVFWFUFKIQN-VIFPVBQESA-N

SMILES: CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F

IUPAC name: (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine

ChEBI definition: The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.

Pharmacological roles (ChEBI): appetite depressant, serotonergic agonist, serotonin uptake inhibitor.

Also known as: D-fenfluramine, Dexfenfluramina, Dexfenfluramine, Fenfluramine d-form, Isolipan, J13.711A, S 5614, dexfenfluramine, DEXFENFLURAMINE

Parent form; salt/anhydrous children: CHEMBL1887891

Patent coverage: 3,781 distinct patent families (15,303 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 15,289 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, Sigma non-opioid intracellular receptor 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SIGMAR1	6.66	Ki	217	nM	CHEMBL_ACT_7685295
SIGMAR1	6.29	IC50	516	nM	CHEMBL_ACT_7685294
P19327	5.71	Ki	1944	nM	CHEMBL_ACT_7685277
P19327	5.47	IC50	3403	nM	CHEMBL_ACT_7685276

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01296802	Not specified	COMPLETED	Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).